MENQUADFI SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE; MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE; MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE; MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE; TETANUS TOXOID

Pieejams no:

SANOFI PASTEUR LIMITED

ATĶ kods:

J07AH08

SNN (starptautisko nepatentēto nosaukumu):

MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED

Deva:

10MCG; 10MCG; 10MCG; 10MCG; 55MCG

Zāļu forma:

SOLUTION

Kompozīcija:

MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10MCG; MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10MCG; MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10MCG; MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE 10MCG; TETANUS TOXOID 55MCG

Ievadīšanas:

INTRAMUSCULAR

Vienības iepakojumā:

100

Receptes veids:

Schedule D

Ārstniecības joma:

VACCINES

Produktu pārskats:

Active ingredient group (AIG) number: 0562558001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-10-29

Produkta apraksts

PAGE 1 OF 37
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MENQUADFI
™
Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid
Conjugate Vaccine
Solution for injection
Active Immunizing Agent for the Prevention of Invasive Meningococcal
Disease
ATC code: J07AH08
Sanofi Pasteur Limited
Toronto, Ontario, Canada
Date of Approval:
October 29, 2020
Submission Control No: 233632
Sanofi Pasteur
395 MenQuadfi
TM
Product Monograph
PAGE 2 OF 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................
4
1.2
Geriatrics
...........................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
DOSAGE AND ADMINISTRATION
.............................................................................
4
3.1
Recommended Dose
.........................................................................................................
4
3.2
Administration
..................................................................................................................
5
4
OVERDOSAGE
................................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............... 5
6
DESCRIPTION
.................................................................................................................
6
7
WARNINGS AND PRECAUTIONS
...............................................................................
7
7.1
Special Populations
...................................................................................................